Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.150
-0.015 (-1.29%)
At close: May 15, 2026, 4:00 PM EDT
1.140
-0.010 (-0.87%)
After-hours: May 15, 2026, 4:54 PM EDT
Pliant Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
49
Market Cap
71.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.58M | -8.11M | -83.69% |
| Dec 31, 2022 | 9.69M | 2.11M | 27.91% |
| Dec 31, 2021 | 7.57M | -34.25M | -81.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 63.26M |
| Gossamer Bio | 48.47M |
| ImmuCell | 27.64M |
| Seres Therapeutics | 1.15M |
| Rallybio | 858.00K |
| MediciNova | 409.66K |
PLRX News
- 4 days ago - Pliant Therapeutics reports Q1 EPS (32c), consensus (36c) - TheFly
- 4 days ago - Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 9 days ago - Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 15 days ago - Pliant Therapeutics doses first participant in FORTIFY expansion trial - TheFly
- 15 days ago - Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - GlobeNewsWire
- 26 days ago - Pliant announces presentation of updated data from Phase 1 trial of PLN-101095 - TheFly
- 27 days ago - Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting - GlobeNewsWire
- 6 weeks ago - Pliant Therapeutics files $300M mixed securities shelf - TheFly